drugset / Trial / NCT00002634

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

NCT00002634

Phase 2 Completed 45 enrolled Memorial Sloan Kettering Cancer Center
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy, radiation therapy, immunotherapy, and bone marrow transplantation in treating patients with neuroblastoma.

Timeline

Start
1995-02
Primary completion
2004-09
Completion
2004-09

Publications

  • Background Cheung NV, Kushner BH, LaQuaglia MP, et al.: Anti-Gd2 monoclonal antibody (MOAB) 3F8-targeted therapy and dose intensity for children (1 yr of age) with stage 4 neuroblastoma (NB): key variables in sequential protocols at Memorial Sloan Kettering Cancer Center (MSKCC). [Abstract] Proceedings of the American Society of Clinical Oncology 19: A-2305, 2000.

Drugs

EvaluationDrugModalityDoseRoute
Subject 3F8 Monoclonal antibody Intravenous
Subject Cisplatin Other / unclassified Intravenous
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Doxorubicin Other / unclassified Intravenous
Subject Etoposide Small molecule
Subject Vincristine Small molecule Intravenous
Subject perfosfamide Small molecule
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule
Background filgrastim Protein / enzyme biologic Intravenous

Indications